Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Formisano, Luigi | - |
dc.contributor.author | Lu, Yao | - |
dc.contributor.author | Servetto, Alberto | - |
dc.contributor.author | Hanker, Ariella B. | - |
dc.contributor.author | Jansen, Valerie M. | - |
dc.contributor.author | Bauuer, Joshua A. | - |
dc.contributor.author | Sudhan, Dhivya R. | - |
dc.contributor.author | Guerrero-Zotano, Angel L. | - |
dc.contributor.author | Croessmann, Srah | - |
dc.contributor.author | Guo, Yan | - |
dc.contributor.author | Ericsson, Paula Gonzalez | - |
dc.contributor.author | Lee, Kyung min | - |
dc.contributor.author | Nixon, Mellissa J. | - |
dc.contributor.author | Schwarz, Luis J. | - |
dc.contributor.author | Sanders, Melinda E. | - |
dc.contributor.author | Dugger, Teresa C. | - |
dc.contributor.author | Cruz, Marcelo Rocha | - |
dc.contributor.author | Behdad, Amir | - |
dc.contributor.author | Cristofanilli, Massimo | - |
dc.contributor.author | Bardia, Aditya | - |
dc.contributor.author | O'Shaughnessy, Joyce | - |
dc.contributor.author | Nagy, Rebecca J. | - |
dc.contributor.author | Lanman, Richard B. | - |
dc.contributor.author | Solovieff, Nadia | - |
dc.contributor.author | He, Wei | - |
dc.contributor.author | Miller, Michelle | - |
dc.contributor.author | Su, Fei | - |
dc.contributor.author | Shyr, Yu | - |
dc.contributor.author | Mayer, Ingrid A. | - |
dc.contributor.author | Balko, Justin M. | - |
dc.contributor.author | Arteaga, Carlos L. | - |
dc.date.accessioned | 2022-07-10T01:06:09Z | - |
dc.date.available | 2022-07-10T01:06:09Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2019-03 | - |
dc.identifier.issn | 2041-1723 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/148135 | - |
dc.description.abstract | Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer cells and MCF-7 cells transduced with FGFR1 were resistant to fulvestrant ± ribociclib or palbociclib. This resistance was abrogated by treatment with the FGFR tyrosine kinase inhibitor (TKI) lucitanib. Addition of the FGFR TKI erdafitinib to palbociclib/fulvestrant induced complete responses of FGFR1-amplified/ER+ patient-derived-xenografts. Next generation sequencing of circulating tumor DNA (ctDNA) in 34 patients after progression on CDK4/6 inhibitors identified FGFR1/2 amplification or activating mutations in 14/34 (41%) post-progression specimens. Finally, ctDNA from patients enrolled in MONALEESA-2, the registration trial of ribociclib, showed that patients with FGFR1 amplification exhibited a shorter progression-free survival compared to patients with wild type FGFR1. Thus, we propose breast cancers with FGFR pathway alterations should be considered for trials using combinations of ER, CDK4/6 and FGFR antagonists. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE RESEARCH | - |
dc.title | Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Kyung min | - |
dc.identifier.doi | 10.1038/s41467-019-09068-2 | - |
dc.identifier.scopusid | 2-s2.0-85063448552 | - |
dc.identifier.wosid | 000462288800004 | - |
dc.identifier.bibliographicCitation | NATURE COMMUNICATIONS, v.10, no.1, pp.1 - 14 | - |
dc.relation.isPartOf | NATURE COMMUNICATIONS | - |
dc.citation.title | NATURE COMMUNICATIONS | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 14 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | ACQUIRED-RESISTANCE | - |
dc.subject.keywordPlus | PHARMACOLOGICAL INHIBITION | - |
dc.subject.keywordPlus | AMPLIFICATION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | PALBOCICLIB | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | ABEMACICLIB | - |
dc.identifier.url | https://www.nature.com/articles/s41467-019-09068-2 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.